Vaderis Therapeutics Secures $152 Million in Latest Series B Funding Round

Vaderis Therapeutics secured $152 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Vaderis Therapeutics Raises $152 million in Funding

Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROI. Vaderis is a science-driven, patient-focused biotech with a singular aim: to be the first to bring breakthrough therapies to people with HHT and other rare vascular diseases.

Investors Behind the Funding

The round was backed by Stealth. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Vaderis Therapeutics operates in Healthcare & Life Sciences. Vaderis Therapeutics's financing adds to recent private-market activity.

Strategic Use of Funds

Treat Hereditary Haemorrhagic Telangiectasia (HHT), a rare vascular disease.

Looking Ahead

Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROI

Source reference: original announcement/article.